-
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
3.13.2024WilmerHale represented Siolta Therapeutics, Inc., a biotech company developing live biotherapeutics that target the core drivers of disease, in its $12 million Series C Preferred Stock financing.
-
Recent Venture Financings as Company Counsel: 2024
2.16.2024In 2023, we served as counsel in more than 150 venture financings raising over $4 billion, including some of the largest and most prominent deals of the year.
-
Cornell University, WilmerHale Collaborate to Publish Startup Launch Booklet for Entrepreneurs and Founders of Emerging Companies
11.28.2023Together, WilmerHale and Cornell University have collaborated in a joint effort to publish Startup Launch – Liftoff with Legal 101 for Entrepreneurs, a booklet for startup founders to think early about key items that will set them off on the right legal track.
-
WilmerHale Named Venture Capital Firm of the Year by LMG Life Sciences
9.12.2023LMG Life Sciences has named WilmerHale as the Venture Capital Firm of the Year in its 11th annual awards.
-
WilmerHale Advises Georgiamune on $75M Series A Financing
8.14.2023On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody.
-
2023 M&A Report
3.31.2023The 2023 M&A Report provides a broad, global M&A market review and outlook, plus insights on several important topics.
-
2023 Venture Capital Report
3.31.2023The 2023 Venture Capital Report offers an in-depth US venture capital market review and outlook, including regional and industry breakdowns, along with insights on key topics.
-
2023 IPO Report
3.31.2023The 2023 IPO Report shares a detailed look at the IPO market and provides useful market metrics and need-to-know information on topics that affect pre-IPO companies.
-
2023 IPO, Venture Capital and M&A Reports
3.31.2023WilmerHale’s annual IPO, Venture Capital and M&A reports offer detailed insights into market conditions and provide comprehensive statistics and thoughtful analysis.
-
Recent Venture Financings as Company Counsel: 2023
3.9.2023In 2022, we served as counsel in more than 200 venture financings raising over $7 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing
12.8.2022On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale.
-
2022 IPO, Venture Capital and M&A Reports
2.28.2022WilmerHale’s annual IPO, Venture Capital and M&A reports provide insights into market conditions, as well as comprehensive statistics and analysis that are hard to find elsewhere.
-
2022 Venture Capital Report
2.28.2022The 2022 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
2022 M&A Report
2.28.2022The 2022 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2022 IPO Report
2.28.2022The 2022 IPO Report offers a detailed IPO market review and outlook, including regional breakdowns, plus useful market metrics and articles on topics of interest for pre-IPO companies